Development and Validation of a Streamlined Multiplex RT-PCR Assay for Accurate SARS-CoV-2 Detection in Diverse Healthcare Environments
Current Microbiology · 2026
DOI: 10.1007/s00284-026-04798-1 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Current Microbiology, 2026. Verfasst von Kauser Banu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shankaranarayana Life Sciences LLP (SNLS), 144-C/1, Kirloskar Road, Bommasandra Industrial Estate, Hebbagodi, Bengaluru, 560100, Karnataka, India. Hauptthemen laut MEDLINE: SARS-CoV-2, Multiplex Polymerase Chain Reaction, COVID-19, COVID-19 Nucleic Acid Testing. Die Arbeit nennt 51 Literaturangaben.
Abstract (Originalsprache)
The global spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has triggered an extraordinary global disturbance. According toWHO epidemiological reports (June 2025) indicate the COVID-19 pandemic has resulted in approximately 778 million confirmed infections and 7 million attributable fatalities globally. The swift mutation of SARS-CoV-2 and the arrival of multiple variants highlight the critical need for rapid, accurate diagnostic assays to monitor and mitigate public health risks. This study presents the development and validation of a multiplex reverse transcription-PCR (RT-PCR) assay designed for sensitive and specific SARS-CoV-2 detection. The assay simultaneously targets two highly conserved viral genes (ORF1ab and N) along with human RNase P as an internal control. Comprehensive analytical validation using plasmid standards (1.5–150,000 copies/µL) confirmed a limit of detection (LOD) of 1.5 copies/µL, high amplification efficiency (97.7–102.2%), and excellent reproducibility (coefficient of variation < 5%). Clinical evaluation with 193 patient samples (N = 193:102 positive, 91 negative) demonstrated 100% concordance with commercial assays (diagnostic sensitivity/specificity: 100%), with results achievable in < 90 min. This rigorously validated, platform-independent assay provides a cost-effective and efficient diagnostic option, meeting WHO target product profile requirements and is suitable for use in both high-throughput and resource-limited laboratory settings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shankaranarayana Life Sciences LLP (SNLS), 144-C/1, Kirloskar Road, Bommasandra Industrial Estate, Hebbagodi, Bengaluru, 560100, Karnataka, India.
- Department of Biotechnology, Rashtreeya Vidyalaya College of Engineering, RVCE, Mysore Rd, RV Vidyaniketan Post, Bengaluru, 560059, Karnataka, India.
- Shankaranarayana Life Sciences LLP (SNLS), 144-C/1, Kirloskar Road, Bommasandra Industrial Estate, Hebbagodi, Bengaluru, 560100, Karnataka, India. drmondal@snlifesciences.com.
Zitieren
APA
Banu, K., Mondal, B., Lekhana, K. G., Raviteja, N., Sudha, C. S., Kumar, S. M., & Raju, H. (2026). Development and Validation of a Streamlined Multiplex RT-PCR Assay for Accurate SARS-CoV-2 Detection in Diverse Healthcare Environments. Current Microbiology. https://doi.org/10.1007/s00284-026-04798-1
Vancouver
Banu K, Mondal B, Lekhana KG, Raviteja N, Sudha CS, Kumar SM, et al. Development and Validation of a Streamlined Multiplex RT-PCR Assay for Accurate SARS-CoV-2 Detection in Diverse Healthcare Environments. Current Microbiology. 2026. doi:10.1007/s00284-026-04798-1
BibTeX
@article{Banu2026,
author = {Banu, Kauser and Mondal, Bhairab and Lekhana, K G and Raviteja, N and Sudha, C Sai and Kumar, S Madan and Raju, H},
title = {Development and Validation of a Streamlined Multiplex RT-PCR Assay for Accurate SARS-CoV-2 Detection in Diverse Healthcare Environments},
journal = {Current Microbiology},
year = {2026},
doi = {10.1007/s00284-026-04798-1}
}
EUVIMED